secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001493152-23-027346
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma Q2 2023 net loss $4.7M; cash $48.0M; LP-184 IND cleared, LP-284 IND imminent
--------------------------------------------------------------------------------

- Cash and equivalents $48.0M at June 30, 2023 ($55.2M at Dec 2022); cash runway into 2025.
- Net loss $4.7M ($0.44/shr) vs $4.5M ($0.41/shr) in Q2 2022; R&D expenses up to $3.6M from $3.0M.
- FDA cleared IND for LP-184; Phase 1 basket trial activated for solid tumors and brain cancers.
- LP-284 IND submission expected August 2023; Phase 1 trial targeted for Q4 in non-Hodgkin's lymphomas.
- Dosed first patients in Phase 2 Harmonic trial for never-smoker NSCLC; RADR collaboration with Bielefeld University for ADCs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000149315223027346/0001493152-23-027346-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000149315223027346/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-027346

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer